Nov62024The importance of giving patients a voice in the approval of new sickle cell treatment HM Government TwitterLinkedinFacebookemailThis case study is an example of how the MHRA is benefiting from patients providing their lived experience for the pre-authorisation stage of the benefit-risk review. Follow this news feed:
